THIS TERMINATION AGREEMENT is effective as of June 1, 2010 (the “Effective Date”) between
MEDIMMUNE, LLC., a limited liability corporation organized and existing under the laws of Delaware
(“MEDIMMUNE”) and CORNERSTONE THERAPEUTICS INC., a corporation organized and existing
under the laws of Delaware (“CTI”).
NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants herein contained,
the Parties hereby agree as follows:
As of the Effective Date, CTI and MEDIMMUNE hereby terminate the Exclusive License and Collaboration
Agreement effective as of July 30, 2003 by and between MEDIMMUNE and CTI, and any amendments made
thereto, and the rights and licenses granted thereunder and any and all rights and obligations thereunder, including
those incurred prior to, as of or subsequent to the Effective Date, and no rights or obligations of the Exclusive
License and Collaboration Agreement will survive such termination, including but not limited to the obligations of
Section 10.4 of the Exclusive License and Collaboration Agreement notwithstanding anything in the Exclusive
License and Collaboration Agreement to the contrary
IN WITNESS WHEREOF , the Parties have executed this Agreement as of the date(s) set forth below.
Cornerstone Therapeutics Inc.
BY: /s/ Sun Park
BY: /s/ Andrew Powell
TITLE: VP, Business Development